Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Gastroenterol Hepatol
    October 2025
  1. JIANG P, Li Y, Tian J, Luo Y, et al
    Efficacy and safety of biologic therapy for Crohn's disease: An overview of meta-analyses and systematic reviews.
    Gastroenterol Hepatol. 2025;48:502432.
    >> Share

    September 2025
  2. ROCHE PC, Casanovas-Marsal JO, Lopez SG, Lidon RV, et al
    TRANSLATION AND PSYCHOMETRIC EVALUATION OF THE SPANISH VERSION OF THE INFLAMMATORY BOWEL DISEASE KNOWLEDGE (IBD-KNOW) QUESTIONNAIRE.
    Gastroenterol Hepatol. 2025 Sep 9:502576. doi: 10.1016/j.gastrohep.2025.502576.
    >> Share

  3. LOPEZ-CALLEJA AM, Cauce BL, Colomino MI, Martin BV, et al
    Fatigue in patients with Inflammatory Bowel Disease: a descriptive cross-sectional study.
    Gastroenterol Hepatol. 2025 Sep 7:502557. doi: 10.1016/j.gastrohep.2025.502557.
    >> Share

    August 2025
  4. ELOSUA A, Nantes O, Chaparro M, Zabalza L, et al
    Early Advanced Therapies and Real-World Outcomes in Crohn's Disease: A Population-Based Comparison of Two Incident Cohorts in Navarra.
    Gastroenterol Hepatol. 2025 Aug 31:502540. doi: 10.1016/j.gastrohep.2025.502540.
    >> Share

  5. RODRIGUEZ-LAGO I, Casas-Deza D, Rimola J, Calafat M, et al
    Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU) position paper for the management of non-perianal fistulizing Crohn's disease.
    Gastroenterol Hepatol. 2025;48:502450.
    >> Share

  6. CARVAJAL F, Herrera K, Nunez P, Flores L, et al
    Evaluation of remission in ulcerative colitis: Relationship between clinical, endoscopic, and histological markers as predictors of relapse.
    Gastroenterol Hepatol. 2025;48:502437.
    >> Share

  7. ANDRES L, Iborra M, Vicente R, Arias L, et al
    High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: results of a Spanish multicentre observational study.
    Gastroenterol Hepatol. 2025;48:502379.
    >> Share

    July 2025
  8. JULIAO-BANOS F, Parra-Izquierdo V, Pacheco T, Leano JTA, et al
    Epidemiology and Healthcare Resource Utilization in Inflammatory Bowel Disease in Colombia between 2017-2021: A Retrospective Claims Database Study.
    Gastroenterol Hepatol. 2025 Jul 16:502532. doi: 10.1016/j.gastrohep.2025.502532.
    >> Share

  9. PINERO G, Castillo E, Gonzalez-Munoza C, Calm A, et al
    Predictors of early immunosuppression at ulcerative colitis onset in the biological era.
    Gastroenterol Hepatol. 2025 Jul 16:502533. doi: 10.1016/j.gastrohep.2025.502533.
    >> Share

  10. MANOSA M, Calafat M, Francia E, Riba F, et al
    GETECCU POSITION PAPER ON FRAGILITY, ADVANCED AGE AND INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2025 Jul 12:502529. doi: 10.1016/j.gastrohep.2025.502529.
    >> Share

  11. CASELLAS F, Gutierrez-Casbas A, Rodriguez C, Gisbert JP, et al
    EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-alpha as first- or second-line biologic treatment among patients with ulcerative colitis.
    Gastroenterol Hepatol. 2025 Jul 11:502528. doi: 10.1016/j.gastrohep.2025.502528.
    >> Share

    June 2025
  12. GISBERT JP, Chaparro M
    Etrasimod: Review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis.
    Gastroenterol Hepatol. 2025;48:502363.
    >> Share

  13. ROBLES-ALONSO V, Solans R, Lastiri E, Serra X, et al
    Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD.
    Gastroenterol Hepatol. 2025;48:502258.
    >> Share

    May 2025
  14. HERRERO-RODRIGUEZ S, Martin-Cordero L, Mayordomo R, Galvez I, et al
    Sex-based differences in the relationship between health-related quality of life, physical activity, and inflammatory markers in people with Crohn's disease.
    Gastroenterol Hepatol. 2025 May 30:502494. doi: 10.1016/j.gastrohep.2025.502494.
    >> Share

  15. INIESTA-NAVALON C, Rentero-Redondo L, Gomez-Espin R, Saorin MR, et al
    Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes "Infliximab trough levels variability in inflammatory bowel disease".
    Gastroenterol Hepatol. 2025 May 23:502472. doi: 10.1016/j.gastrohep.2025.502472.
    >> Share

  16. CORREAL EN, Gomez DM, Sequeiros AR, Gonzalo FM, et al
    Insights into the status of the quality of nursing care in patients with inflammatory bowel disease: A nationwide survey (The MAPEA Project).
    Gastroenterol Hepatol. 2025 May 14:502464. doi: 10.1016/j.gastrohep.2025.502464.
    >> Share

  17. GIORDANO A, Baston I, Madero L, Brunet-Mas E, et al
    Unraveling the Gut-Fat-Inflammation Connection in Crohn's Disease: A Path to New Therapeutic Targets?
    Gastroenterol Hepatol. 2025 May 14:502466. doi: 10.1016/j.gastrohep.2025.502466.
    >> Share

  18. MINGUEZ A, Coello E, Garrido A, Ripoll P, et al
    Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
    Gastroenterol Hepatol. 2025;48:502253.
    >> Share

    April 2025
  19. CARVAJAL F, Herrera K, Nunez P, Flores L, et al
    CHALLENGES IN ADHERENCE TO STRIDE-II: PERSPECTIVES FROM GASTROENTEROLOGISTS AND PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2025 Apr 3:502440. doi: 10.1016/j.gastrohep.2025.502440.
    >> Share

    March 2025
  20. SAVIO MC, Coelho JC, Oliveira E, Magro DO, et al
    Nationwide Trends in Colectomy Rates for Ulcerative Colitis in Brazil: An Analysis of the Unified Public Healthcare System.
    Gastroenterol Hepatol. 2025 Mar 20:502434. doi: 10.1016/j.gastrohep.2025.502434.
    >> Share

  21. GINARD D, Fontanillas N, Baston-Rey I, Pejenaute ME, et al
    Position statement of the Spanish Society of Primary Care Physicians (SEMERGEN) and Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the management of inflammatory bowel disease in Primary Care.
    Gastroenterol Hepatol. 2025;48:502255.
    >> Share

    February 2025
  22. FERREIRA SDC, Parra RS, Sassaki LY, Miguel Luz Parente J, et al
    CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS: A COMPARATIVE REAL-WORLD MULTICENTRIC OBSERVATIONAL STUDY.
    Gastroenterol Hepatol. 2025 Feb 21:502396. doi: 10.1016/j.gastrohep.2025.502396.
    >> Share

  23. FONSECA CB, Petry R, Harlacher L, Hanauer L, et al
    Body mass index does not influence loss of response to tumor necrosis factor inhibitors in Crohn's disease.
    Gastroenterol Hepatol. 2025 Feb 4:502372. doi: 10.1016/j.gastrohep.2025.502372.
    >> Share

    January 2025
  24. ZHENG D, Qinke X, Jin W, Zhouyue G, et al
    Prevalence and Bidirectional Association Between Primary Sclerosing Cholangitis and Crohn's disease: A Systematic Review and Meta-Analysis.
    Gastroenterol Hepatol. 2025 Jan 18:502346. doi: 10.1016/j.gastrohep.2025.502346.
    >> Share

  25. MORENO ALFONSO JC, Barbosa-Velasquez S, Delgado-Miguel C, Molina Caballero A, et al
    EXPLORING THE UTILITY OF CELLULAR INDICES IN THE DIAGNOSIS OF ULCERATIVE COLITIS.
    Gastroenterol Hepatol. 2025 Jan 17:502349. doi: 10.1016/j.gastrohep.2025.502349.
    >> Share

  26. KINOSHITA K, Sawaguchi S, Toyoshima K, Yoshida S, et al
    Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis.
    Gastroenterol Hepatol. 2025 Jan 9:502347. doi: 10.1016/j.gastrohep.2025.502347.
    >> Share

    December 2024
  27. PERIS MA, Francisco JDH, Mateu PN, Piudo AE, et al
    Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2024 Dec 11:502320. doi: 10.1016/j.gastrohep.2024.502320.
    >> Share

  28. GONZALEZ-MUNOZA C, Gely C, Gordillo J, Calafat M, et al
    Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2024;47:502193.
    >> Share

  29. RODRIGUEZ-LAGO I, Herrera-deGuise C, Bosca-Watts M, Rodriguez C, et al
    Combination of granulocyte-monocyte apheresis and ustekinumab: Multicentre and retrospective study.
    Gastroenterol Hepatol. 2024;47:502195.
    >> Share

    November 2024
  30. CARRASCO MF, Fernandez AP, Garcia OS
    Hyperinfestation by strongyloides stercolaris in an immunodepressed patient due to inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 Nov 29:502317. doi: 10.1016/j.gastrohep.2024.502317.
    >> Share

  31. MARIN-JIMENEZ I, Carpio D, Hernandez V, Munoz F, et al
    Spanish Working Group in Crohn s disease and ulcerative colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 Nov 28:502314. doi: 10.1016/j.gastrohep.2024.502314.
    >> Share

  32. FARRUKH A, Mayberry JF
    Inflammatory Bowel Disease in the Gypsy Community in England and Scotland.
    Gastroenterol Hepatol. 2024 Nov 22:502295. doi: 10.1016/j.gastrohep.2024.502295.
    >> Share

  33. OLIVERA PA, Balderramo DC, Lasa JS, Zubiaurre I, et al
    Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe inflammatory bowel disease in Argentina: Data from the RISE-AR study.
    Gastroenterol Hepatol. 2024 Nov 14:502287. doi: 10.1016/j.gastrohep.2024.502287.
    >> Share

    October 2024
  34. RAMOS L, Marin-Jimenez I
    Disease clearance in ulcerative colitis: what is it? What does it involve? How do we translate it into spanish?
    Gastroenterol Hepatol. 2024 Oct 28:502281. doi: 10.1016/j.gastrohep.2024.502281.
    >> Share

  35. SILVA RL, da Silva E Sousa FI, Silva GLFD, Almeida VDR, et al
    The impact of anxiety and depression on quality of life in a cohort of inflammatory bowel disease patients from northeastern of brazil.
    Gastroenterol Hepatol. 2024 Oct 28:502283. doi: 10.1016/j.gastrohep.2024.502283.
    >> Share

  36. INIESTA-NAVALON C, Rios-Saorin M, Rentero-Redondo L, Anez-Castano R, et al
    Comparative evaluation of Point of Care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients.
    Gastroenterol Hepatol. 2024 Oct 21:502277. doi: 10.1016/j.gastrohep.2024.502277.
    >> Share

  37. OLIVERA PA, Parks ML, Pellegrini D, Finn B, et al
    Incidence and prevalence of inflammatory bowel diseases in a population from Buenos Aires, Argentina.
    Gastroenterol Hepatol. 2024;47:804-812.
    >> Share

    September 2024
  38. FERNANDEZ CARRASCO M, Delgado Maroto A, Hernandez Martinez A
    CEREBRAL THROMBOSIS AS A MANIFESTATION OF POOR CONTROL IN INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2024 Sep 28:502256. doi: 10.1016/j.gastrohep.2024.502256.
    >> Share

  39. RUEDA GARCIA JL, Benitez JM, Baston Rey I, Calafat Sard M, et al
    Thromboembolic phenomena in inflammatory bowel disease and risk with JAK inhibitor treatments.
    Gastroenterol Hepatol. 2024 Sep 19:502257. doi: 10.1016/j.gastrohep.2024.502257.
    >> Share

  40. FISSAH M, Rechach A, Charifi M, Menzou F, et al
    Increased arterial stiffness in Crohn's disease: prevalence, associated factors and impact of anti-TNF therapy.
    Gastroenterol Hepatol. 2024 Sep 11:502252. doi: 10.1016/j.gastrohep.2024.502252.
    >> Share

    August 2024
  41. DIAZ MOLINA RJ, Comesana Castellar C, Crespi Rigo J, Radu Tomsa C, et al
    DESCRIPTIVE OBSERVATIONAL STUDY ON THE USE OF VIRTUAL REALITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDERGOING BIOLOGICAL TREATMENT.
    Gastroenterol Hepatol. 2024 Aug 20:502236. doi: 10.1016/j.gastrohep.2024.502236.
    >> Share

  42. CARLOS GONCALVES J, Arieira C, Xavier S, Magalhaes J, et al
    Small Bowel Crohn's Disease: Proximal Lesions Linked to Increased Inflammation and Biologic Treatment Needs.
    Gastroenterol Hepatol. 2024 Aug 5:502235. doi: 10.1016/j.gastrohep.2024.502235.
    >> Share

  43. FRAGA-BLANCO P, Boullon-Batalla N, Benitez JM, Suarez-Ferrer C, et al
    What strategies do we employ in the prevention andmonitoring of human papillomavirus inpatients with inflammatory bowel disease?
    Gastroenterol Hepatol. 2024;47:771-773.
    >> Share

  44. RODRIGUEZ-LAGO I, Canete F, Guerra-Del-Rio E, Herrera-deGuise C, et al
    Combination of granulocyte-monocyte apheresis and tofacitinib: Multicentre and retrospective study.
    Gastroenterol Hepatol. 2024;47:727-733.
    >> Share

  45. SUAREZ FERRER C, Martin-Arranz E, Martin-Arranz MD
    Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital.
    Gastroenterol Hepatol. 2024;47:721-726.
    >> Share

  46. LORAS C, Piqueras M, Ruiz P, Zaffalon D, et al
    Duodenal stenosis in a Crohn's disease patient treated with lumen apposing metal stent.
    Gastroenterol Hepatol. 2024;47:759-760.
    >> Share

    July 2024
  47. CALDERON P, Nunez P, Herrera K, Flores L, et al
    Evaluation of the sensitivity and specificity of sigmoidoscopy in comparison to colonoscopy regarding the detection of intestinal inflammatory activity in the follow-up of patients with ulcerative colitis.
    Gastroenterol Hepatol. 2024 Jul 17:502232. doi: 10.1016/j.gastrohep.2024.502232.
    >> Share

  48. VIDAL-DELSO M, Fortuny M, Gonzalez-Gonzalez L, Pelach A, et al
    Strongyloides stercolaris hiperinfection syndrome in ulcerative colitis treated with corticotherapy. The importance of strongyloides screening.
    Gastroenterol Hepatol. 2024 Jul 9:502230. doi: 10.1016/j.gastrohep.2024.502230.
    >> Share

    May 2024
  49. LOPEZ-SERRANO A, Cabaleiro AV, Ramon Lorente Montoro J, Gomez FJS, et al
    Artificial intelligence for dysplasia detection during surveillance colonoscopy in patients with ulcerative colitis: a cross-sectional, non-inferiority, diagnostic test comparison study.
    Gastroenterol Hepatol. 2024 May 11:502210. doi: 10.1016/j.gastrohep.2024.502210.
    >> Share

  50. GRAVINA AG, Pellegrino R, Palladino G, Imperio G, et al
    Profiling the patient with inflammatory bowel disease in the relationship between physical activity and partner/social network status: a post-hoc patient-tailored analysis of the "BE-FIT-IBD" study**.
    Gastroenterol Hepatol. 2024 May 7:502203. doi: 10.1016/j.gastrohep.2024.502203.
    >> Share

  51. LAGO IR, Gros B, Sanchez K, Arumi D, et al
    Use of digital health tools in inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 May 7:502200. doi: 10.1016/j.gastrohep.2024.502200.
    >> Share

  52. COSTA CA, Ferrer CS, Ramirez LG, Arranz EM, et al
    EVALUATION OF THE TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2024 May 7:502201. doi: 10.1016/j.gastrohep.2024.502201.
    >> Share

  53. DA SILVA E SOUSA FI, Silva RL, Rabelo Lemos Filho CN, Pereira Santos MTO, et al
    VACCINE ADHERENCE AND ADVERSE EVENTS OF THE SARS-COV VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2024 May 7:502202. doi: 10.1016/j.gastrohep.2024.502202.
    >> Share

  54. CALVO BERNAL MDM, Campos EP, Mota AA, Martinez AH, et al
    ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2024 May 6:502192. doi: 10.1016/j.gastrohep.2024.502192.
    >> Share

  55. RAMOS COZAR SN, Masot RM, Gallego BR, Rubio L, et al
    Assessment of the length of sick leave in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 May 5:502194. doi: 10.1016/j.gastrohep.2024.502194.
    >> Share

  56. FERNANDEZ-PEREZ FJ, Moreno NF, Lopez ES, Rodriguez-Gonzalez FJ, et al
    GRANULOCYTE AND MONOCYTE ADSORPTIVE APHERESIS (GMA) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A USEFUL THERAPEUTIC TOOL NOT JUST IN ULCERATIVE COLITIS BUT ALSO IN CROHN S DISEASE.
    Gastroenterol Hepatol. 2024 May 4:502196. doi: 10.1016/j.gastrohep.2024.502196.
    >> Share

  57. FERRER CS, Gismero FM, Caballol B, Ballester MP, et al
    EFFICACY AND SAFETY OF BIOLOGICAL TREATMENT FOR INFLAMMATORY BOWEL DISEASE IN ELDERLY PATIENTS: RESULTS FROM A GETECCU COHORT.
    Gastroenterol Hepatol. 2024 May 4:502197. doi: 10.1016/j.gastrohep.2024.502197.
    >> Share

  58. RODRIGUEZ-MORANTA F, Arguelles-Arias F, Hinojosa Del Val J, Iborra Colomino M, et al
    Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.
    Gastroenterol Hepatol. 2024;47:522-552.
    >> Share

    April 2024
  59. FUENTES-VALENZUELA E, Carbajo AY, Fernandez-Prada SJ, Rubiales BM, et al
    Beyond Crohn's disease: Deferasirox as possible agent for drug-induced ileocolitis.
    Gastroenterol Hepatol. 2024;47:380-381.
    >> Share

  60. RODRIGUEZ-LAGO I, Abecia L, Seoane I, Anguita J, et al
    An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis.
    Gastroenterol Hepatol. 2024;47:347-351.
    >> Share

    March 2024
  61. NAVARRO-GERRARD C, Calafat M, Benitez JM, Suarez-Ferrer C, et al
    Are biologic agents effective and safe in patients with IBD and solid organ transplantation?
    Gastroenterol Hepatol. 2024;47:289-292.
    >> Share

  62. LASA J, Smolarczuk A, Navar S, Ponce C, et al
    Endoscopic scoring system utilization for inflammatory bowel disease activity assessment: A multicenter real-world study from Argentina.
    Gastroenterol Hepatol. 2024;47:253-261.
    >> Share

    February 2024
  63. CALM A, Calafat M, Gonzalez-Munoza C, Canete F, et al
    Incidence of herpes zoster in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 Feb 3:S0210-5705(24)00032.
    >> Share

  64. VARA-LUIZ F, Mendes I, Teles AE, Oliveira C, et al
    Malignant transformation in fistula after proctosigmoidectomy: A rare complication of longstanding Crohn's Disease.
    Gastroenterol Hepatol. 2024 Feb 3:S0210-5705(24)00033.
    >> Share

  65. PARRA V, Cifuentes S, Avendano S, de Leon EP, et al
    Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease-EXVEDOCOL.
    Gastroenterol Hepatol. 2024 Feb 2:S0210-5705(24)00025.
    >> Share

    January 2024
  66. DOMENECH E, Ciudin A, Balibrea JM, Coll EE, et al
    Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Span
    Gastroenterol Hepatol. 2024 Jan 28:S0210-5705(23)00502.
    >> Share

  67. PEREZ JP, Ortiz JE, Franco Moreno AI, Plaza Santos MDR, et al
    Influence of HLA-DQA1 *05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice.
    Gastroenterol Hepatol. 2024 Jan 22:S0210-5705(24)00020.
    >> Share

  68. DEZA DC, Julian Gomara AB, Biota EC, Beltran B, et al
    IMPACT OF MESALAZINE ON THE RESPONSE TO COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTRE STUDY OF GETECCU (VACOVEII STUDY).
    Gastroenterol Hepatol. 2024 Jan 12:S0210-5705(24)00017.
    >> Share

  69. MOYA MC, Gismero FM, Ferrer CS, Hernandez-Camba A, et al
    Position Statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on Sexuality and Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2024 Jan 11:S0210-5705(24)00019.
    >> Share

  70. BALDERRAMO D, Yamamoto-Furusho J, Ponce de Leon E, de Maria J, et al
    Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
    Gastroenterol Hepatol. 2024;47:51-62.
    >> Share

  71. GRAU G, Altadill A, Brunet-Mas E, Calvet X, et al
    Cyclosporine treatment for severe steroid refractory immune-mediated colitis in a patient with ulcerative colitis.
    Gastroenterol Hepatol. 2024;47:72-73.
    >> Share

    December 2023
  72. NONES RB, Miranda EF, Nardi Marcal G, Barbosa Barauna FDS, et al
    Infliximab serum concentrations in luminal Crohn's Disease and its relationship with disease activity: a multicentric cross-sectional study.
    Gastroenterol Hepatol. 2023 Dec 29:S0210-5705(23)00505.
    >> Share

  73. CALDERON P, Nunez P, Nos P, Quera R, et al
    Personalized therapy in inflammatory bowel disease.
    Gastroenterol Hepatol. 2023 Dec 13:S0210-5705(23)00497.
    >> Share

  74. BASTIDA G, Alvarez-Sotomayor D, Aguas M, Iborra M, et al
    Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
    Gastroenterol Hepatol. 2023 Dec 8:S0210-5705(23)00491.
    >> Share

  75. GARCIA-ALANIS M, Toapanta-Yanchapaxi L, Reyes-Velasquez A, Mancilla F, et al
    The interrelation between anxiety and quality of life among patients with ulcerative colitis in remission.
    Gastroenterol Hepatol. 2023;46:747-753.
    >> Share

    November 2023
  76. DEZA DC, Julian Gomara AB, Biota EC, Beltran B, et al
    A BOOSTER DOSE OF SARS-CoV-2 VACCINE IMPROVES SUBOPTIMAL SEROCONVERSION RATES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTER STUDY OF GETECCU (VACOVEII STUDY).
    Gastroenterol Hepatol. 2023 Nov 23:S0210-5705(23)00474.
    >> Share

  77. PENA MEJIA LA, Ruiz Nino GV, Arteta Cueto AA
    Relation between histopathological findings, clinical severity, and the need of surgery in patients with Crohn's disease.
    Gastroenterol Hepatol. 2023 Nov 23:S0210-5705(23)00473.
    >> Share

  78. MANUEL BENITEZ J, Suarez-Ferrer C, Calafat M, Baston-Rey I, et al
    Paediatric to adult transition programme in inflammatory bowel disease, why do we need it?
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00469.
    >> Share

  79. GONZALEZ-MUNOZA C, Gely C, Gordillo J, Bertoletti F, et al
    Duration of smoking cessation in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00470.
    >> Share

    October 2023
  80. SILVA ACV, Tumelero TJ, Yamamoto DR, Truppel SK, et al
    Biological therapy, surgery, and hospitalization rates for inflammatory bowel disease: an observational Latin American comparative study between adults and pediatric patients.
    Gastroenterol Hepatol. 2023 Oct 25:S0210-5705(23)00452.
    >> Share

  81. IZQUIERDO VP, Frias-Ordonez JS, Cuadros C, Vargas M, et al
    Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience.
    Gastroenterol Hepatol. 2023 Oct 9:S0210-5705(23)00442.
    >> Share

  82. PINERO G, Manosa M, Calafat M, Vayreda E, et al
    Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00439.
    >> Share

  83. IZQUIERDO VP, Frias-Ordonez JS, Banos FJ, Cuadros C, et al
    Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: a case series study.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00443.
    >> Share

  84. LAO DOMINGUEZ FA, Fobelo Lozano MJ, Gutierrez Pizarraya A, Castro Fernandez M, et al
    Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease.
    Gastroenterol Hepatol. 2023;46:631-632.
    >> Share

  85. FORTUNY M, Gutierrez-Rios L, Vayreda E, Manosa M, et al
    Tofacitinib for the treatment of inflammatory condition of the ileoanal pouch refractory to infliximab.
    Gastroenterol Hepatol. 2023;46:629-630.
    >> Share

    August 2023
  86. SERRANO DIAZ L, Iniesta Navalon C, Gomez Espin R, Nicolas De Prado I, et al
    Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study.
    Gastroenterol Hepatol. 2023 Aug 18:S0210-5705(23)00392.
    >> Share

  87. RIOS LG, Vayreda E, Calafat M, Canete F, et al
    Changes in the intensified regimen of infliximab in patients with inflammatory bowel disease in sustained remission. Reflections on a series of cases.
    Gastroenterol Hepatol. 2023 Aug 8:S0210-5705(23)00374.
    >> Share

  88. ARENAS A, Moreta MJ, Ordas I, Fernandez-Clotet A, et al
    De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
    Gastroenterol Hepatol. 2023 Aug 8:S0210-5705(23)00376.
    >> Share

  89. DIAZ LS, Navalon CI, Espin RG, Prado IN, et al
    Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023;46:504-511.
    >> Share

    June 2023
  90. SUAREZ FERRER C, Martin-Arranz MD, Martin-Arranz E, Rodriguez Morata F, et al
    Current management of bowel failure due to Crohn's disease in Spain: Results of a GETECCU survey.
    Gastroenterol Hepatol. 2023;46:439-445.
    >> Share

  91. NAVARRO-CORREAL E, Ibarz Casas A, Agustino Rodriguez S, Marin L, et al
    Knowledge, attitudes and behaviours on smoking cessation in nurses caring for patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023;46:468-471.
    >> Share

    May 2023
  92. BENITO BM, Gisbert JP, Garcia Fraile Fraile LJ, Blandino AB, et al
    SEXUALLY TRANSMITTED INFECTIONS AS A DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2023 May 5:S0210-5705(23)00333.
    >> Share

  93. GONZALEZ-MARTINEZ A, Garcia IM, Quintas S, Chaparro M, et al
    Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics.
    Gastroenterol Hepatol. 2023 May 4:S0210-5705(23)00331.
    >> Share

  94. MENG XF, Lin QY, Yin HL, Li ZQ, et al
    Magnetic resonance imaging for evaluation of bowel inflammation and disease activity in Crohn's disease: A systematic review and meta-analysis.
    Gastroenterol Hepatol. 2023;46:336-349.
    >> Share

    April 2023
  95. PITARCH LG, Almela P, Nos P
    Leishmania infection in patients with Inflammatory Bowel Disease: case series and literature review.
    Gastroenterol Hepatol. 2023 Apr 13:S0210-5705(23)00074.
    >> Share

  96. MORENO EN, Lopez Gonzalez J, Saez ML
    METASTATIC CROHN'S DISEASE WITH ESPLENIC AFECTATION: A VERY RARE CASE.
    Gastroenterol Hepatol. 2023 Apr 4:S0210-5705(23)00073.
    >> Share

  97. GARGALLO-PUYUELO CJ, Garcia-Mateo S, Martinez-Dominguez SJ, Gomollon F, et al
    Is the gender or age of the physician key to a good physician-patient with inflammatory bowel disease relationship?
    Gastroenterol Hepatol. 2023;46:261-265.
    >> Share

  98. RAMOS L, Carrillo-Palau M, Alonso-Abreu I, Reygosa C, et al
    COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
    Gastroenterol Hepatol. 2023;46:255-260.
    >> Share

    March 2023
  99. CASTILLO-REGALADO E, Rios R, Arajol C, Gely C, et al
    Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
    Gastroenterol Hepatol. 2023;46:164-170.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016